Merck Tbk. vs Trimegah Karya Pratama Tbk. — how do they compare? Merck Tbk. trades at Rp3,840 (market cap 1.7T, 37.6K 24h volume), while Trimegah Karya Pratama Tbk. trades at Rp139 (market cap 272.02B, 55.79M 24h volume). The key difference: Merck Tbk. is far larger — about 6.2× Trimegah Karya Pratama Tbk.'s market cap, and Trimegah Karya Pratama Tbk. is more actively traded (55.79M versus 37.6K). Which is the better fit depends on your goals.
| MERK | UVCR | |
|---|---|---|
Market Cap | 1.7T | 272.02B |
Volume | 37.6K | 55.79M |
Lot | 376 | 557.94K |
Turnover | 144.47M | 7.75B |
Average Price | 3,842.23 | 138.88 |
Value | 144.47M | 7.75B |
Indicative Equilibrium Price | 3,840 | 139 |
Indicative Equilibrium Volume | 7 | 6.83K |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Tbk (the Company) is domiciled in Indonesia and located at Jl. TB Simatupang No. 8, Pasar Rebo, East Jakarta, was established in framework of Law No. 1 of 1967 and Law No. 11 of 1970 on foreign capital investment by deed of notary public Eliza Pondaag, SH dated 14 October 1970 No. 29. PT Merck Indonesia is a member of the Merck International Group. The company produces pharmaceutical products with production facility in East Jakarta. It commenced its operation in 1974 in manufacturing medical products, such as Songobian and Neurobion.
Read more on MERK →PT Trimegah Karya Pratama Tbk (the Company) was established based on Notarial Deed No. 21 dated July 7, 2017 of Netty Maria Machdar, S.H. The Company started its commercial operations in 2018. The Company’s immediate parent company is PT Trimegah Sumber Mas, which was established and domiciled in Indonesia, while its ultimate Parent Company is PT Hutama Mulia Rajawali, which was established and domiciled in Indonesia.
Read more on UVCR →